Marcel Nijland
dr.
I work as a hematologist and my main focus is on patients with aggressive B-cell lymphomas and CNS lymphomas. My research is centered on the application of novel diagnostic and therapeutic strategies into clinical trials. These include imaging-studies like 18F-FDG-PET, Zr-Brentuximab-PET and Zr-atezolizumab-PET. In addition, I aim to implement novel strategies to measure minimal residual disease, and prognostic gene expression profiles in DLBCL. Linked to this I also focus on mutational analysis to study clonal evolution and prognostic / predictive values of mutations. These studies are carried out in a close collaboration with HOVON and other departments in the UMCG.
Dynamics of circulating tumour DNA in relapsed/refractory diffuse large B-cell lymphoma patients
Published in: British Journal of Haematology
Access to document
10.1111/bjh.70296
document
The response to salvage chemotherapy in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) is poor, and data on circulating tumour deoxyribonucleic acid (ctDNA) in this setting are limited. We evaluated ctDNA dynamics in 29 patients with relapsed or refractory DLBCL who received platinum-based salvage chemotherapy at the University Medical Center Groningen. In total, 124 plasma samples were analysed using low-coverage whole-genome sequencing to detect copy number alterations (CNAs) and targeted sequencing with a 115-gene panel for single- and multi-nucleotide variants (SNVs/MNVs). The complete response rate at the end...
Yujie Zhong, Johanna Bult, Nick Veltmaat, Filipe Montes de Jesus, Laurens Sillje, Joost Kluiver, Anke van den Berg, Wouter Plattel, Arjan Diepstra, Marcel Nijland
Superior survival in diffuse large B cell lymphoma of the bone with immune rich tumor microenvironment
Published in: Blood cancer journal
Access to document
10.1038/s41408-025-01291-z
document
With tumor genomic and gene-expression profiling (GEP), this study investigated the immune-molecular signatures of a unique cohort of diffuse large B-cell lymphoma of the bone (bone-DLBCL), including primary bone (PB-DLBCL, n = 52) and polyostotic-DLBCL (n = 20), in comparison to nodal DLBCLs with germinal center B-cell (GCB) phenotype (nodal-DLBCL-GCB, n = 34). PB-DLBCL and polyostotic-DLBCL shared similar genomic profiles and transcriptomic signatures, justifying their collective analysis as bone-DLBCL. Differential incidences of EZH2, HIST1H1E, and MYC aberrations (p < 0.05) confirmed the distinct oncogenic evolution between bone-DLBCL and...
Ruben A.L. de Groen, Fleur A. de Groot, Stefan Böhringer, Esther J. Kret, Lorraine M. de Haan, Troy Noordenbos, Susan Blommers, Romée E.W. Jansen, Tom van Wezel, Ronald van Eijk, Richard Raghoo, Dina Ruano, Liane te Boome, Valeska Terpstra, Henriette Levenga, Els Ahsmann, Eduardus F.M. Posthuma, Isabelle Focke-Snieders, Lizan Hardi, Wietske C.E. den HartogAnke van den Berg, Pim Mutsaers, King Lam, Marjolein W.M. van der Poel, Myrurgia Abdul Hamid, F. J.Sherida H. Woei-A-Jin, Ann Janssens, Thomas Tousseyn, Judith V.M.G. Bovée, Lianne Koens, Arjan Diepstra, Arjen H.G. Cleven, Marie José Kersten, Patty M. Jansen, Hendrik Veelken, Marcel Nijland, Tim J.A. Dekker, Joost S.P. Vermaat
Fixed-duration epcoritamab plus R2drives favorable outcomes in relapsed or refractory follicular lymphoma
Published in: Blood
Access to document
10.1182/blood.2025029909
document
Epcoritamab is a subcutaneous CD3×CD20 bispecific antibody approved as monotherapy for relapsed/refractory (R/R) follicular lymphoma (FL). We evaluated fixed-duration epcoritamab with rituximab plus lenalidomide (R2) in R/R FL in arm 2 of EPCORE NHL-2 (phase 1b/2). Patients received epcoritamab (2 step-up doses, then 48-mg full doses) for up to 2 years, and R2for up to 12 cycles (28 days per cycle). The primary end point was overall response rate (ORR) per investigator assessment (Lugano criteria). As of 21 September 2024, 108 patients received ≥1 epcoritamab dose in expansion...
Lorenzo Falchi, Anna Sureda, Sirpa Leppä, Joost S.P. Vermaat, Marcel Nijland, Jacob Haaber Christensen, Sven de Vos, Harald Holte, Reid W. Merryman, Pieternella J. Lugtenburg, Pau Abrisqueta, Kim M. Linton, Gauri Sunkersett, Daniela Hoehn, Ali Rana, Aqeel Abbas, Jennifer Marek, Yi Hao, Andrew J. Steele, Christopher MorehouseMartin Hutchings, David Belada
MATRix and HD-MTX/IFO/DEP treatment and autologous stem cell transplantation in secondary central nervous system lymphoma: a Dutch retrospective analysis
Published in: Haematologica
Access to document
10.3324/haematol.2025.287485
document
Fleur A De Groot, Floriske G Stedema, Esther J Kret, Lorraine M De Haan, Patty M Jansen, Stefan Böhringer, Arjan Diepstra, Marjolein W M Van der Poel, Myrurgia Abdul Hamid, Liane C J Te Boome, Valeska Terpstra, Mirian Brink, Hendrik Veelken, Ruben A L De Groen, Tim J A Dekker, Marcel Nijland, Joost S P Vermaat
Non-inferior outcome of abbreviated R-CHOP in patients with stage I primary testicular lymphoma
Published in: European Journal of Cancer
Access to document
10.1016/j.ejca.2025.115776
document
BACKGROUND: Patients with limited-stage primary testicular lymphoma (PTL) typically receive a multimodal regimen, including 6 cycles of R-CHOP, despite limited evidence. In low-risk diffuse large B-cell lymphoma, de-escalation to 4 R-CHOP cycles has proven non-inferior. It remains unclear whether similar de-escalation is feasible in PTL. METHODS: Patients aged ≥ 18 years with Ann Arbor stage I-II PTL diagnosed between 2014 and 2021 were identified in the Netherlands Cancer Registry. Patients receiving ≥ 3 R-CHOP cycles were included. Outcomes were 5-year progression-free survival (PFS), overall survival (OS), and cumulative incidence function...
Diana Al-Sarayfi, Johanna A A Bult, Ruben A L de Groen, Fleur A de Groot, Joost S P Vermaat, Djamilla Issa, Arjan Diepstra, Gerwin Huls, Mar Bellido, Wouter Plattel, Mirian Brink, Marcel Nijland